Lp(a) vs ApoB: What’s the Difference, and Do You Need Both Tests?

Lipoprotein(a), usually written Lp(a), and apolipoprotein B, or ApoB, are both blood markers that can reveal cardiovascular risk that a standard cholesterol panel may not fully capture. But they do not measure the same thing, and one is not simply a more advanced version of the other.

ApoB reflects the overall number of cholesterol-carrying particles capable of contributing to atherosclerosis. Lp(a), by contrast, measures a particular type of lipoprotein particle whose level is largely inherited. An Lp(a) particle contains ApoB, so the two markers are biologically connected, but an ApoB result cannot tell you whether your Lp(a) is elevated.

That distinction matters when deciding whether either—or both—tests may add useful information to LDL cholesterol, triglycerides, and the rest of a conventional lipid panel. Current U.S. guidance recommends measuring Lp(a) at least once in adulthood, while ApoB testing is used more selectively to refine cardiovascular risk and guide lipid-lowering treatment.

Lp(a) and ApoB are related, but they are not interchangeable

The easiest way to understand the difference is to think about specific particle type versus total particle burden.

ApoB is a structural protein found on the major lipoprotein particles associated with atherosclerosis, including very-low-density lipoproteins (VLDL), intermediate-density lipoproteins (IDL), LDL particles, remnant particles, and Lp(a). Because each of these atherogenic particles carries one ApoB molecule, the blood concentration of ApoB provides a practical estimate of how many such particles are circulating.

Lp(a) is much more specific. It is an LDL-like particle containing ApoB-100 with an additional protein called apolipoprotein(a), or apo(a), attached to it. That added apo(a) component gives Lp(a) biological characteristics that distinguish it from ordinary LDL particles.

This means an Lp(a) particle contributes to the ApoB measurement because it contains ApoB. But ApoB combines Lp(a) with all the other ApoB-containing particles in circulation. It does not separate Lp(a) from the rest.

Put another way:

ApoB asks: How many atherogenic lipoprotein particles are circulating overall?

Lp(a) asks: How much of this particular inherited lipoprotein risk factor do you have?

Those are related questions, but they are not the same question.

A quick comparison of Lp(a) and ApoB

Feature	Lp(a)	ApoB
What it measures	A specific LDL-like lipoprotein containing apo(a)	ApoB carried by the major atherogenic lipoprotein particles
What the result mainly tells you	Whether an inherited Lp(a)-related source of cardiovascular risk is present	The overall concentration of circulating atherogenic particles
Main influence on level	Predominantly genetics	Genetics, metabolism, diet, body weight, health conditions, and lipid-lowering treatment can all influence ApoB-containing particles
Relationship to LDL	Lp(a) has an LDL-like component but has additional properties because of apo(a)	Includes LDL particles as well as other ApoB-containing particles
Typical units	nmol/L or mg/dL	mg/dL
Current testing approach	At least once in adulthood	Selectively when it can improve risk assessment or treatment decisions
Does the other test replace it?	No	No

The comparison also explains why ordering both is not necessarily redundant.

Why ApoB can reveal risk that LDL cholesterol misses

A standard lipid panel usually reports LDL cholesterol, or LDL-C. LDL-C measures the amount of cholesterol carried inside LDL particles. It does not directly tell you how many LDL particles are present.

Those two measurements often move together, but not always.

Imagine two people carrying the same total amount of cargo. One could carry it in 10 large containers, while another carries it in 20 smaller containers. The total cargo might be identical even though the number of containers differs.

A similar form of discordance can occur with lipoproteins. Two people with similar LDL-C can have different numbers of ApoB-containing particles because individual particles can carry different amounts of cholesterol.

That matters because atherosclerosis depends in part on ApoB-containing particles entering and becoming retained within the artery wall. When LDL-C and ApoB are discordant, evidence suggests cardiovascular risk tends to track more closely with ApoB or non-HDL cholesterol than with LDL-C alone.

This situation is particularly relevant in people with metabolic conditions in which triglyceride-rich particles and cholesterol-depleted LDL particles may be more common.

The 2026 ACC/AHA dyslipidemia guideline therefore says ApoB measurement can be useful for improving risk assessment and guiding therapy, especially in circumstances such as elevated triglycerides, diabetes, cardiovascular-kidney-metabolic syndrome, established atherosclerotic cardiovascular disease, or very low LDL-C achieved during treatment.

For a more detailed explanation of this mismatch between cholesterol concentration and particle burden, see our guide to the ApoB test and LDL-C discordance.

What Lp(a) reveals that ApoB cannot

Lp(a) addresses a different blind spot.

Your Lp(a) concentration is predominantly determined by variants in the LPA gene and tends to remain relatively stable through much of life. Lifestyle habits that substantially affect LDL-C, triglycerides, or other metabolic markers generally have much less influence on Lp(a) itself. Certain health states and life stages can alter the measurement, but for most people it functions primarily as an inherited cardiovascular risk marker.

Elevated Lp(a) is associated with a higher risk of atherosclerotic cardiovascular disease, including heart attack and stroke, and with calcific aortic valve disease. Its risk contribution can remain relevant even when LDL-C is comparatively low.

That is why a normal-looking LDL-C—or even a reassuring ApoB result—does not automatically rule out elevated Lp(a).

The 2026 ACC/AHA guideline recommends that Lp(a) be measured at least once to identify people with this additional source of risk. It considers an Lp(a) concentration of 125 nmol/L or 50 mg/dL and above a risk-enhancing factor, although Lp(a)-related risk occurs across a continuum rather than switching on abruptly at one number.

For a fuller explanation of who should be tested, inherited risk, units, and result interpretation, see our guide to the lipoprotein(a) test.

Does ApoB already include Lp(a)?

Technically, yes—but that does not make an Lp(a) measurement unnecessary.

Each Lp(a) particle contains one molecule of ApoB-100. If you measure total ApoB, the ApoB associated with Lp(a) is therefore included along with ApoB from LDL, VLDL, IDL, and other atherogenic particles.

The problem is that total ApoB does not tell you the source of those particles.

Suppose an ApoB result represents 100 units of total particle burden for illustration. The test itself cannot tell you whether very little of that burden comes from Lp(a) or whether Lp(a) makes a meaningful contribution. A separate Lp(a) assay is needed to identify the specific Lp(a) concentration.

This is particularly important because Lp(a)’s cardiovascular relevance is not simply a matter of adding one more ordinary LDL-like particle to the total. The attached apo(a) protein and associated biological properties make Lp(a) a distinct risk factor.

Can Lp(a) be high when ApoB is normal?

Yes.

A person can have an elevated Lp(a) concentration without having an obviously elevated total ApoB result. The remainder of that person’s ApoB-containing particle burden may simply be low enough that total ApoB does not cross a particular clinical threshold.

The reverse is also possible. ApoB may be elevated because someone has a large number of LDL or triglyceride-rich remnant particles even when Lp(a) is low.

That produces four broadly different patterns:

Lp(a) elevated, ApoB not elevated

This suggests a specific Lp(a)-related risk factor is present even though total atherogenic particle burden may not appear unusually high by ApoB.

The Lp(a) finding still matters. Current guidance treats elevated Lp(a) as a reason to pay closer attention to overall cardiovascular risk and to optimize modifiable risk factors rather than dismissing the result because another lipid marker looks favorable.

ApoB elevated, Lp(a) not elevated

Here, Lp(a) may not be an important contributor, but the person still has an increased concentration of other atherogenic particles.

Depending on the broader clinical picture, addressing that ApoB-containing particle burden may become an important part of lipid management.

Both Lp(a) and ApoB are elevated

These findings point to two overlapping issues: elevated overall atherogenic particle burden and an elevated concentration of Lp(a).

They should not be interpreted by simply adding the two laboratory numbers together. They use different units and describe different biological information. Instead, clinicians consider them alongside LDL-C, non-HDL-C, triglycerides, blood pressure, diabetes status, smoking, family history, established cardiovascular disease, age, and other risk factors.

Neither is elevated

This can be reassuring from a lipoprotein perspective, but it does not mean cardiovascular risk is zero. Blood pressure, smoking, diabetes, kidney disease, age, family history, inflammation, and existing plaque can influence risk independently of these two tests.

Neither Lp(a) nor ApoB is intended to function as a stand-alone cardiovascular diagnosis.

Why Lp(a) results may be reported in two different units

One potentially confusing difference is how the tests are reported.

ApoB is generally reported in milligrams per deciliter (mg/dL).

Lp(a) may appear as either nanomoles per liter (nmol/L), which reflects particle concentration, or mg/dL, which reflects mass concentration.

It is tempting to search for a simple mathematical conversion between the two Lp(a) units, but experts advise against using a universal conversion factor. The apo(a) portion of Lp(a) varies substantially in molecular size from person to person, so a single conversion can produce misleading results. The National Lipid Association favors reporting Lp(a) in nmol/L when possible and recommends against converting between nmol/L and mg/dL using a fixed multiplier.

If a laboratory reports Lp(a) in mg/dL, however, the result can still be clinically useful. It should simply be interpreted using thresholds appropriate for that measurement method rather than converted with an internet calculator.

So, do you need both Lp(a) and ApoB tests?

For many adults, there is a reasonable case for having information from both at some point—but the recommendations for the two tests are not identical.

Lp(a): broadly recommended at least once

The 2026 ACC/AHA dyslipidemia guideline recommends Lp(a) measurement at least once in adulthood. Because levels are predominantly inherited and generally stable, repeated testing is usually unnecessary unless a clinical circumstance could have changed the result or a clinician has another reason to reassess it.

This means Lp(a) is increasingly being treated less like a specialized test reserved only for unusual cases and more like a marker that adults should generally know at least once.

ApoB: useful more selectively

The same guideline does not call for universal ApoB testing in every adult.

Instead, ApoB can be particularly useful when a conventional lipid panel may not adequately describe the number of atherogenic particles or when clinicians are deciding whether further lipid-lowering therapy is appropriate.

Examples include people with elevated triglycerides, type 2 diabetes, cardiovascular-kidney-metabolic syndrome, established cardiovascular disease, or low LDL-C achieved during treatment. ApoB may also help when LDL-C, non-HDL-C, triglycerides, and the person’s overall risk profile seem to tell conflicting stories.

So the answer to “Do I need both?” is not simply yes or no.

Lp(a) and ApoB provide complementary information. Current guidance supports at least one adult Lp(a) measurement, while whether ApoB adds enough information to be worthwhile depends more on the person’s lipid pattern, medical history, treatment status, and overall cardiovascular risk.

What these tests should not be used for

Neither test should be interpreted in isolation.

A high Lp(a) result does not mean someone will inevitably have a heart attack or stroke. Likewise, an ApoB result by itself does not establish whether a person should begin, stop, or change cholesterol-lowering medication.

Clinical decisions depend on the complete risk picture. That can include LDL-C and non-HDL-C, triglycerides, blood pressure, diabetes, kidney function, smoking, family history, existing cardiovascular disease, age, and in selected cases other tools such as coronary artery calcium scoring.

It is also important not to assume that a laboratory’s “normal range” is automatically the optimal treatment target for an individual. ApoB goals can vary according to cardiovascular risk and treatment context, while Lp(a)-associated risk occurs along a continuum.

Anyone using these measurements to make treatment decisions should have the results interpreted in the context of their medical history by a qualified healthcare professional.

The practical difference to remember

If you remember only one distinction, make it this:

ApoB describes how many atherogenic lipoprotein particles are circulating overall. Lp(a) identifies one particular, largely inherited type of atherogenic particle.

Because every Lp(a) particle contains ApoB, the tests overlap biologically. But they answer different clinical questions, and neither can reliably substitute for the other.

For most adults, current guidelines support finding out Lp(a) at least once. ApoB becomes especially informative when doctors need a clearer picture of particle burden than LDL-C and the conventional lipid panel provide.

Together, the measurements can help explain why two people with similar LDL cholesterol numbers may not have the same lipoprotein-related cardiovascular risk.

References

1. Blumenthal RS, Morris PB, et al. “2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia.” Circulation, 2026.
2. Koschinsky ML, Bajaj A, Boffa MB, et al. “A Focused Update to the 2019 NLA Scientific Statement on Use of Lipoprotein(a) in Clinical Practice.” Journal of Clinical Lipidology, 2024.
3. Soffer DE, Marston NA, Maki KC, et al. “Role of Apolipoprotein B in the Clinical Management of Cardiovascular Risk in Adults: An Expert Clinical Consensus from the National Lipid Association.” Journal of Clinical Lipidology, 2024.
4. Gaudet D, Larouche M, Raal FJ, Catapano AL. “New and Emerging Therapeutic Targets for ApoB-Containing Particles Lowering.” Circulation Research, 2026.